` BHC (Bausch Health Companies Inc) vs S&P 500 Comparison - Alpha Spread

BHC
vs
S&P 500

Over the past 12 months, BHC has underperformed S&P 500, delivering a return of -8% compared to the S&P 500's +14% growth.

Stocks Performance
BHC vs S&P 500

Loading
BHC
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BHC vs S&P 500

Loading
BHC
S&P 500
Difference
www.alphaspread.com

Performance By Year
BHC vs S&P 500

Loading
BHC
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Bausch Health Companies Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Bausch Health Companies Inc
Glance View

Bausch Health Companies Inc. stands as a prominent player in the global healthcare arena, with its roots stretching back over a century. Originally known as Valeant Pharmaceuticals, the firm has undergone significant transformation, focusing on a diverse array of health-related products and innovations. The company operates primarily in three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. Each of these divisions articulates its commitment to enhancing patients' lives through high-quality products that address the complex challenges of eye care, gastroenterology, and dermatology, respectively. The Bausch + Lomb sector, named after its foundational company, is recognized globally for its wealth of eye health products, including contact lenses, lens care products, and ophthalmic pharmaceuticals. This sector is integral to Bausch Health's revenue stream, contributing significantly through its diverse portfolio of over-the-counter and prescription offerings. At its core, Bausch Health has honed a business model centered around acquiring and developing specialty pharmaceuticals and health-enhancing technologies. Through strategic acquisitions, partnerships, and internal research, the company curates a vast pipeline of treatments and solutions. Revenue generation for Bausch Health is intrinsically linked to its global market footprint, operating in more than 100 countries. Sales teams across these regions work diligently to ensure that healthcare professionals and consumers alike have access to their products. Meanwhile, the company's commitment to innovation helps it remain responsive in rapidly evolving medical fields. The sales and marketing strategies are finely tuned to address regional disparities, leveraging local insights to maximize market penetration and bolster growth. Ultimately, Bausch Health Companies Inc. thrives by bridging high-quality health solutions with unmet global needs, seeking to leave a lasting impact on the lives it touches.

BHC Intrinsic Value
66.26 USD
Undervaluation 90%
Intrinsic Value
Price
Back to Top